Glecaprevir/pibrentasvir shows safety, efficacy in patients with HCV, renal disease

A recent study has shown that 102 out of 104 HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe HCV and liver disease.

Learn more here: bit.ly/2fyxLVE

oldestnewest